

Todd M Pitts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11387659/publications.pdf>

Version: 2024-02-01

54
papers

2,561
citations

257450

24
h-index

197818

49
g-index

54
all docs

54
docs citations

54
times ranked

5724
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-derived tumour xenografts as models for oncology drug development. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 338-350.	27.6	1,091
2	Targeting nuclear kinases in cancer: Development of cell cycle kinase inhibitors. , 2014, 142, 258-269.		75
3	Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras Mutated Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 3351-3362.	4.1	71
4	Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development. <i>Clinical Cancer Research</i> , 2010, 16, 3193-3204.	7.0	70
5	Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 342-349.	4.1	62
6	Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4149-4162.	7.0	61
7	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 849-860.	7.0	58
8	Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models. <i>Clinical Cancer Research</i> , 2013, 19, 6219-6229.	7.0	53
9	Development of new preclinical models to advance adrenocortical carcinoma research. <i>Endocrine-Related Cancer</i> , 2018, 25, 437-451.	3.1	45
10	A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 82.	5.0	44
11	Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 317-325.	4.1	43
12	Assessment of the <i>In vivo</i> Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line-Derived Human Colorectal Cancer Xenograft Models. <i>Clinical Cancer Research</i> , 2010, 16, 2989-2998.	7.0	42
13	Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models. <i>Clinical Cancer Research</i> , 2012, 18, 1051-1062.	7.0	41
14	Common PIK3CA Mutants and a Novel 3' UTR Mutation Are Associated with Increased Sensitivity to Saracatinib. <i>Clinical Cancer Research</i> , 2012, 18, 2704-2714.	7.0	41
15	Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2546-2558.	4.1	40
16	Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models. <i>Clinical Cancer Research</i> , 2013, 19, 291-303.	7.0	40
17	Dual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal Cancer. <i>PLoS ONE</i> , 2014, 9, e113037.	2.5	40
18	The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models. <i>Clinical Cancer Research</i> , 2010, 16, 5436-5446.	7.0	38

#	ARTICLE	IF	CITATIONS
19	ALK Inhibitor Response in Melanomas Expressing <i>EML4-ALK</i> Fusions and Alternate <i>ALK</i> Isoforms. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 222-231.	4.1	38
20	The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance. <i>Oncotarget</i> , 2016, 7, 28273-28285.	1.8	34
21	Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2112-2122.	4.1	33
22	Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. <i>Frontiers in Pharmacology</i> , 2013, 4, 35.	3.5	32
23	p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1117-1129.	4.1	32
24	Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer. <i>Frontiers in Pharmacology</i> , 2013, 4, 22.	3.5	30
25	Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. <i>Oncotarget</i> , 2016, 7, 50290-50301.	1.8	27
26	Biliverdin Reductase B Dynamics Are Coupled to Coenzyme Binding. <i>Journal of Molecular Biology</i> , 2018, 430, 3234-3250.	4.2	22
27	Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models. <i>Frontiers in Pharmacology</i> , 2015, 6, 120.	3.5	21
28	First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β -Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1916-1925.	4.1	21
29	Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. <i>Cancer Research</i> , 2018, 78, 5398-5407.	0.9	20
30	Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 94.	2.8	19
31	First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1598-1612.	4.1	19
32	Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes. <i>Frontiers in Immunology</i> , 2021, 12, 607282.	4.8	19
33	Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination. <i>Clinical Cancer Research</i> , 2019, 25, 3352-3365.	7.0	18
34	The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy. <i>Oncotarget</i> , 2017, 8, 110904-110913.	1.8	18
35	RX-5902, a novel β -catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer. <i>BMC Cancer</i> , 2020, 20, 1063.	2.6	16
36	Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	15

#	ARTICLE	IF	CITATIONS
37	Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. <i>Investigational New Drugs</i> , 2016, 34, 176-183.	2.6	15
38	Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924). <i>Investigational New Drugs</i> , 2017, 35, 11-25.	2.6	15
39	Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 719.	3.7	15
40	Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC. <i>Endocrine-Related Cancer</i> , 2019, 26, 765-778.	3.1	15
41	Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer. <i>BMC Cancer</i> , 2018, 18, 136.	2.6	13
42	WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 642328.	2.8	13
43	An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer. <i>BMC Genomics</i> , 2015, 16, S2.	2.8	12
44	Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts. <i>Oncotarget</i> , 2015, 6, 34561-34572.	1.8	10
45	Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models. <i>Anti-Cancer Drugs</i> , 2018, 29, 827-838.	1.4	9
46	Structure, dynamics and function of the evolutionarily changing biliverdin reductase B family. <i>Journal of Biochemistry</i> , 2020, 168, 191-202.	1.7	9
47	Procedure for Horizontal Transfer of Patient-Derived Xenograft Tumors to Eliminate. <i>Journal of the American Association for Laboratory Animal Science</i> , 2017, 56, 166-172.	1.2	9
48	Preclinical Development of the Class-I Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 397-406.	4.1	8
49	A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer. <i>Oncologist</i> , 2018, 23, 1409-e140.	3.7	7
50	Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alistertib) in Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 4633-4642.	7.0	7
51	Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors. <i>Molecular Carcinogenesis</i> , 2020, 59, 1227-1240.	2.7	6
52	Modulating Enzyme Function via Dynamic Allostery within Biliverdin Reductase B. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 691208.	3.5	5
53	Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. <i>Clinical Cancer Drugs</i> , 2018, 5, 42-49.	0.3	4
54	HDAC and PD-1 inhibition in humanized triple-negative breast cancer xenografts. <i>Journal of Clinical Oncology</i> , 2017, 35, e14604-e14604.	1.6	0